top of page

European Commission approves Sobi and Ionis' Tryngolza for severe hypertriglyceridaemia

Writer: nuaxia
nuaxia
29 minutes ago
2 min read

The European Commission has approved Tryngolza for adults with severe hypertriglyceridaemia, following Phase III results showing substantial triglyceride reductions and fewer acute pancreatitis events.


On 17 November 2026, the European Commission approved Tryngolza (olezarsen), developed by Ionis Pharmaceuticals and commercialised by Sobi in its licensed territories, as an adjunct to diet and other lipid-lowering therapies for adults with severe hypertriglyceridaemia and fasting triglyceride concentrations of at least 880 mg/dL.


The Phase III CORE and CORE2 studies reported mean triglyceride reductions of up to 73% at six months and an 83% reduction in acute pancreatitis event rates compared with placebo; this represents a final European Commission marketing authorisation rather than a preliminary CHMP recommendation, with national access dependent on subsequent commercial and reimbursement arrangements.

Field

Content

Companies

Sobi and Ionis Pharmaceuticals

Medicine

Tryngolza (olezarsen)

Regulatory Authority

European Commission

Approval Date

17 November 2026

Approval Type

EU marketing authorisation

Therapeutic Area

Cardiometabolic medicine

Indication

Severe hypertriglyceridaemia

Eligible Patients

Adults with fasting triglycerides of at least 880 mg/dL

Treatment Regimen

Adjunct to diet and other lipid-lowering therapies

Drug Modality

RNA-targeted medicine

Supporting Studies

Phase III CORE and CORE2

Triglyceride Reduction

Mean reductions of up to 73% at six months

Pancreatitis Outcome

83% reduction in acute pancreatitis event rates versus placebo

Development Partner

Ionis Pharmaceuticals

Commercialisation Partner

Sobi in licensed territories outside the US excluding Canada and China

Regulatory Significance

Final European Commission approval; not merely a positive CHMP opinion

Primary Source

https://www.sobi.com/en/press-releases/tryngolzatm-olezarsen-approved-eu-severe-hypertriglyceridaemia-shtg-2498693


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page